References
- Carranza-LiraSActualidades en terapia hormonal Universum-Mexico.2008
- Carranza-LiraSCortés-FuentesEModification of vasomotor symptoms after different treatment modalities in the postmenopauseInt J Gynaecol Obstet200173216917111336741
- UtianWHShoupeDBachmannGPinkertonJVPickarJHRelief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetateFertil Steril200175661065107911384629
- RossouwJEAndersonGLPrenticeRLRisk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women’s Health Initiative randomized controlled trialJAMA2002288332133312117397
- HarmanSMEstrogen replacement in menopausal women: Recent and current prospective studies, the WHI and the KEEPSGend Med20063425426917582367
- Figueroa-CasasPREttingerBDelgadoEJavkinAViederCReversal by medical treatment of endometrial hyperplasia caused by estrogen replacement therapyMenopause20018642042311723414
- LoboRAAbsorption and metabolic effects of different types of estrogen and progestogensObstet Gynecol Clin North Am19871411431673306517
- JacksonVPSan MartinJASecrestRJComparison of the effect of raloxifene and continuous combined hormone replacement therapy on mammographic breast density and breast tenderness in postmenopausal womenAm J Obstet Gynecol2003188238939412592245
- GenazzaniARMannellaPSimonciniTDrospirenone and its antialdosterone propertiesClimacteric200710Suppl 1111817364593
- Sitruk-WareRPharmacology of different progestogens: the special case of drospirenoneClimacteric20058Suppl 341216203650
- YlikorkalaODrospirenone, a progestin with a unique cardiovascular profile, for safe contraception and treatment of menopausal symptomsClimacteric20058Suppl 31316203649
- LosertWCasals-StenzelJBuseMProgestogens with antimineralocorticoid activityArzeneimuttelforschung1985352459471
- OelkersWBergerVBolikADihydrospirorenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal womenJ Clin Endocrinol Metab19917348378421890155
- OelkersWDrospirenone, a progestogen with antimineralocorticoid properties: a short reviewMol Cell Endocrinol200421712255261
- ArcherDFDrospirenone and estradiol: a new option for the postmenopausal womanClimacteric200710Suppl 131017364592
- SchürmannRHollerTBendaNEstradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimensClimacteric20047218919615497908
- ArcherDFThorneycroftIHFoeghMLong-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trialMenopause200516671672716278615
- LeeBSKangBMYoonBKChoiHParkHMKimJGEfficacy and tolerability of estradiol 1 mg and drospirenone 2 mg in postmenopausal Korean women: A double-blind, randomized, placebo-controlled, multicenter studyMaturitas200757436136917467203
- WhiteWBPittBPrestonRAHanesVAntihypertensive effects of drospirenone with 17 beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertensionCirculation2005112131979198416186434
- WhiteWBHanesVChauhanVPittBEffects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertensionHypertension2006482243253
- MallareddyMHanesVWhiteWBDrospirenone, a new progestogen, for postmenopausal women with hypertensionDrugs Aging200724645346617571911
- PanayNStuddJProgestogen intolerance and compliance with hormone replacement therapy in menopausal womenHum Reprod Update1977321591719286739
- SherwinBBGelfandMMA prospective one-year study of estrogen and progestin in postmenopausal women: effects on clinical symptoms and lipoprotein lipidsObstet Gynecol198973(5 pt 1)7597662704504
- Sitruk-WareRPharmacological profile of progestinsMaturitas200447427728315063480